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Abstract
BACKGROUND—Populations at risk for esophageal adenocarcinoma remain poorly defined.
Laryngeal symptoms can be secondary to laryngopharyngeal reflux (LPR) and can occur without
associated gastroesophageal reflux symptoms such as heartburn and regurgitation.
GOAL—We sought to determine the prevalence of Barrett’s esophagus (BE) in otolaryngology
patients with laryngeal symptoms ± typical GERD symptoms.
STUDY—We performed a cross-sectional study of otolaryngology clinic patients who reported
laryngeal symptoms. Symptoms, medications and exposure histories were obtained. Unsedated
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transnasal endoscopy was performed. Suspected BE was biopsied and confirmed histologically.
Risk factors and prevalence of BE were assessed.
RESULTS—Two hundred and ninety five patients were enrolled (73% male, median age 60
[IQR 51–68]). The overall prevalence of BE was 11.8% (n=33). Antisecretory medication use was
present in 56% (n=156) of patients at enrollment. Compared to patients without BE, patients with
BE were more likely to be male (p=0.01) and to report occupational lung injury (p=0.001).
Duration, but not severity of laryngeal symptoms, significantly increased the odds of Barrett’s
esophagus (OR 5.64 [95% CI 1.28, 24.83] for a duration of symptoms > 5 years). Of patients with
BE, 58% (n=19) had co-existing LPR and GERD symptoms and 30% (n=10) had only LPR
symptoms. Presence and size of hiatal hernia and length of columnar lined esophagus were
significant risk factors for BE.
CONCLUSIONS—Long-standing laryngeal symptoms are associated with the presence of BE in
otolaryngology patients. Patients with chronic laryngeal symptoms and no identifiable ear, nose,
or throat etiology for those symptoms may benefit from endoscopic screening regardless of
whether typical GERD symptoms are present.
Keywords
Laryngeal symptoms; gastroesophageal reflux disease; screening; otolaryngology; Barreet’s
esophagus; unsedated transnasal endoscopy
INTRODUCTION
The association between gastroesophageal reflux disease (GERD), Barrett’s esophagus
(BE), and esophageal adenocarcinoma (EAC) is well established. Despite efforts to screen
patients with chronic symptoms of GERD for BE, the death rate from esophageal cancer has
continued to increase exponentially over the past 40 years.1 Because chronic typical GERD
symptoms have been used as the principal indication for endoscopic screening, the majority
of what is known about the prevalence of BE and its clinical risk factors has been gleaned
from highly selected GERD populations. However, up to 50% of patients that develop EAC
do not have an antecedent history of GERD symptoms,2 leaving the population at risk for
BE and EAC incompletely described. This statement is supported by the fact that the
majority of patients who develop EAC have never undergone endoscopic screening for BE
prior to cancer diagnosis3 and present with dysphagia and advanced disease.4 Improved risk
stratification for EAC is needed in order to better guide screening efforts, facilitate early
stage detection and reduce mortality.
It has been suggested that laryngopharyngeal reflux (LPR) symptoms, including cough,
dysphonia, excessive throat clearing and globus sensation are common in patients with BE
and may represent a useful and potent clinical risk factor.5 Given that LPR symptoms are
highly prevalent and account for 10% of all outpatient otolaryngology practice visits,6 this
population represents an unexplored and easily accessible group of patients who are
potentially at risk for BE. The aim of this prospective cross-sectional study was to determine
the prevalence of BE in an unselected otolaryngology patient population with LPR
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symptoms using a validated technique for unsedated transnasal endoscopy to perform
primary screening.7
METHODS
Study Design and Protocol
This is a cross-sectional study including all non-cancer patients who presented to the general
otolaryngology clinics of Oregon Health & Science University and the Portland Veteran’s
Administration hospital from February 8, 2005 to June 7, 2007 under the approval of
institutional review board of both institutions. At the time of clinic check-in, every patient
completed a Reflux Symptom Index (RSI) questionnaire along with his or her intake
paperwork (Figure 1).8 The RSI is a validated tool that assesses severity of atypical
symptoms of GERD, specifically laryngeal symptoms such as hoarseness and cough.9
Patients were asked to rate symptoms on a scale of zero (no problem) to 5 (severe problem).
Questionnaires were collected and scored by the study coordinator. All subjects who scored
greater than 2 in at least two of nine RSI symptom categories, or greater than 3 for any
single RSI symptom category were considered eligible and were subsequently contacted by
phone and approached for enrollment. A total RSI score >13 is defined as abnormal per
questionnaire scoring criteria. All enrolled patients underwent primary screening endoscopy
using an outpatient and unsedated approach.7 Patients with a history of prior screening
endoscopy, antireflux surgery, Zenker’s or epiphrenic diverticulum, pregnancy,
anticoagulation therapy, head and neck malignancy, prior laryngeal surgery or trauma,
esophageal varices, vocal cord paralysis, severe medical co-morbidity, or a history of
recurrent epistaxis were excluded from study participation.
Demographics and Stratification of Clinical Symptoms
Detailed demographic data (age, sex, race), medical co-morbidities, allergy, alcohol and
tobacco use, current or prior use of anti-secretory medications and body mass index were
collected from enrolled patients. Using the GERD Health-Related Quality of Life (GERD-
HRQL) questionnaire10 and Short-Form-12 Health Survey11, typical GERD symptoms and
overall quality of life were assessed at the time of enrollment. A GERD-HRQL score >5 is
considered abnormal. Based on questionnaire scores, the clinical symptoms were
categorized to 4 groups: no pathologic GERD or LPR (GERD-HRQL ≤5 and RSI ≤13),
isolated GERD (GERD-HRQL >5 and RSI ≤13), isolated LPR (GERD-HRQL ≤5 and RSI
>13) and both GERD and LPR (GERD-HRQL >5 and RSI >13).
Technique and Classification of Endoscopic Outcomes
Patients underwent unsedated transnasal endoscopy as previously described.7,12 Using a
one-knob, 4.9 mm diameter flexible endoscope with a 2 mm working channel (Olympus
America Inc., Center Valley, PA), transnasal indirect laryngoscopy was performed and
findings such as vocal fold edema, diffuse laryngeal edema and posterior commissure
hypertrophy were recorded using the Reflux Finding Score (RFS).9 The esophagus was then
intubated in coordination with swallowing. Prior to gastric insufflation, the level of the
anatomic esophagogastric junction (where the gastric folds meet the tubular esophagus) was
compared with the squamocolumnar junction (SCJ) in centimeters from the nares. The
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length of columnar-appearing mucosa protruding into the tubular esophagus was defined as
the distance in centimeters from the anatomic esophagogastric junction to the most proximal
aspect of the SCJ. The SCJ was assigned a grade based on the ZAP classification.13 A ZAP
classification of 0 is assigned to a sharp and circular SCJ without tongues of endoscopically
visible columnar epithelium; these patients were considered negative for BE and were not
biopsied. A ZAP classification of I is assigned when the SCJ is irregular with slight tongue-
like protrusions; a ZAP classification of II exhibits distinct and obvious tongues of columnar
epithelium <3 cm, and a ZAP classification of III has tongues of columnar epithelium >3 cm
or a cephalad displacement of the SCJ >3 cm. Patients with a classification of I-III were
considered suspicious for BE and were biopsied. Following the Seattle protocol, four-
quadrant esophageal biopsies with a 1.8 mm needle forceps (Olympus America Inc., Center
Valley, PA) were obtained beginning immediately proximal to the anatomic esophagogastric
junction and extending every 2 cm to the level of the SCJ.14,15 A hiatal hernia was
considered present when the anatomic esophagogastric junction was located proximal to the
crural pinch, and this separation was measured in centimeters. The presence of esophagitis
was documented and scored using the Los Angeles Classification.16 The gastric fundus and
body were examined and a retroflexion view of the cardia was obtained.
Pathologic Examination and Definition of Barrett's Esophagus
All tissue specimens were formalin-fixed, paraffin embedded, and stained with hematoxylin
and eosin. The diagnosis of BE required that two criteria be fulfilled: 1) endoscopically
evident columnar epithelium located within the tubular esophagus thereby triggering a
biopsy; and 2) unequivocal presence of goblet cells within columnar epithelium on
histologic examination of biopsy specimens. One pathologist with expertise in
gastrointestinal pathology examined all biopsy specimens (DAS). When necessary,
additional sections were obtained from tissue blocks to facilitate diagnosis. Well-established
diagnostic criteria were utilized in the assessment of dysplasia.17 Breifly, metaplasia was
defined as replacement of normal squamous lining by a glandular lining of the specialized
intestinal type, which was charaterized by columnar epithelium containing several cell types
such as goblet cells, blue columnar, clear columnar and enterocyte-like cells with brush
borders. Low-grade dysplasia (LGD) was characterized by hyperchromatic, enlarged nuclei
and depletion of cytoplasmic mucin. High-grade dysplasia (HGD) is characterized by
distortion of glandular architecture and dysplastic epithelium on the mucosal surface with
loss of nuclear polarity. There is lack of consistent relationship of nuclei to each other.18
Data Analysis
Data are presented as median and inter-quartile range for continuous variables and
frequencies for categorical variables. Comparisons of demographic data between groups
with and without BE were performed using independent sample t-tests and Mann-Whitney
U test for continuous variables and Fischer’s exact or chi-squared tests for categorical
variables. Univariate and multivariate logistic regression was performed.
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Patient Demographics and Prevalence of BE
Overall, 3,170 subjects were assessed for eligibility, and 523 subjects were considered
eligible. Of these patients, 295 (56%) were enrolled after the phone interview and 278 (VA
hospital, n=151; University hospital, n=127) completed the entire endoscopic examination
(Figure 2). Patients were predominantly male (n=204; 73%) and Caucasian (n=244; 96%).
Mean age and BMI were comparable between the enrollment sites. The overall prevalence
of BE was 11.8% (n=33). BE was more prevalent in males (n=30; 14.7%) than females
(n=3; 4%; p=0.014). Besides occupational lung injury, there was no difference in lifestyle
variables or medical co-morbidities between those with and without BE (Table 1). There
was a higher prevalence of BE at the Veterans Administration hospital compared to the
University hospital (15.3% vs. 7.8%, respectively, p=0.0053). This trend was explained by
differences in gender distribution between sites. At the Veterans Administration hospital,
91.4% of patients were male compared to 51.6% of patients at the University hospital
(p=<0.001). When only male patients were considered, there was no difference in the
prevalence of BE between the two enrollment sites (16% vs. 12%, p=0.471). Anti-secretory
medication use at the time of enrollment was common (n=156; 56%) in otolaryngology
patients with LPR symptoms and did not differ between patients with and without BE
(p=0.266). Similarly, there was no difference in the duration of anti-secretory medication
use between those with and without BE (p=0.712).
Endoscopic Findings and Prevalence of BE
An abnormal Z-line was identified in 142 (51%) patients (ZAP I, n=93; II, n=31; III, n=18)
and all were biopsied (Table 2). Of this group, 31 patients were diagnosed with BE, 2 had
low-grade dysplasia, and there were no patients with high-grade dysplasia or invasive
cancer. Thirty patients with a ZAP classification of II (n=23) or III (n=7) had a columnar-
lined tubular esophagus but did not meet diagnostic criteria for BE due to the absence of
goblets cells on histologic examination. In 9 of these patients, the length of endoscopic
columnar-lined esophagus was ≥3 cm (range, 3 to 10 cm).
Not surprisingly, the endoscopic length of columnar-appearing mucosa in the esophagus was
strongly associated with a BE diagnosis (p=0.026); of patients with a ZAP classification of
III, 61% had a diagnosis of BE. Hiatal hernia was present in 154 (55%) patients. Presence of
hiatal hernia (p=0.015) and hiatal hernia size (p=0.027) were significantly associated with a
diagnosis of BE. There was no association between the endoscopic appearance of the larynx
(p=0.325) or the presence of esophagitis (p=0.299) and a diagnosis of BE (Table 2). A long
duration of LPR symptoms (≥5 years) was associated with increased odds of having BE;
additionally, patients with a ZAP II or III classification and a long duration of LPR
symptoms (≥5 years) were even more likely to have BE (OR 9.2; 95% CI 2.4–36.6) (Table
3).
LPR Symptoms and Prevalence of BE
Overall RSI score did not differ significantly between those with and without a diagnosis of
BE, indicating that increasing symptom severity was not associated with the presence of BE
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(Table 4). Throat clearing (n=246; 88%), post-nasal drip (n=229; 82%), globus sensation
(n=218; 78%), and hoarseness (n=214; 76%) were the most prevalent LPR symptoms in the
study cohort. Comparing the individual RSI questions between those with BE and without
BE, there were no differences in proportions except for cough, which approached
significance for being more common in BE patients (OR 2.6, 95% CI 0.95–6.9). Coexisting
cough and hoarseness was common overall (n=159, 57%) and more prevalent in BE patients
(73% vs. 55%; p=0.062) (Table 4).
Typical GERD symptoms and Prevalence of BE
Overall, the median score on the GERD-HRQL at the time of enrollment was 9 (IQR 4–16).
The overall GERD-HRQL score was comparable between patients with BE and those
without BE (p=0.06). Typical GERD symptoms including heartburn, chest pain, indigestion
or regurgitation, were reported concomitantly by 74% of otolaryngology patients (n=204)
(Table 4). There were 10 of 55 patients (18.2%) with isolated LPR symptoms (i.e., normal
GERD-HRQL score and abnormal RSI score) who had BE (Table 5). There was no
difference in BE prevalence between those patients who had an abnormal questionnaire
score (RSI and/or GERD-HRQL) compared to those with a normal questionnaire score
(13.2% versus 5%, respectively; p=0.190) (Table 5). When all BE patients (n=33) were
stratified by symptom type, the prevalence of BE was highest in patients with both
pathologic GERD and LPR symptoms (58%) followed by those with isolated LPR (30%)
and then isolated GERD (6%) (Table 5).
DISCUSSION
The findings of the present study provide insight into a population of patients likely at risk
for BE and EAC who would not otherwise be identified for screening under current
practices. The BE prevalence in this otolaryngology clinic-based cohort is comparable to
that reported for gastroenterology patients with chronic typical symptoms of GERD.19,20
Several of the well-established BE risk factors in patients with typical GERD symptoms
were also present in otolaryngology patients with laryngeal symptoms. We observed that
patients with a long duration of laryngeal symptoms, regardless of symptom severity, were
at greatest risk for the presence of BE, similar to the relationship between an increasing
duration of heartburn and regurgitation and the prevalence of BE.21 In addition, endoscopic
markers of reflux disease in patients with LPR symptoms (i.e., presence and size of hiatal
hernia, length of columnar-lined epithelium) were also significantly associated with a BE
diagnosis. Finally, there was no correlation between the endoscopic appearance of the larynx
and the presence of BE.
One of the primary challenges encountered in the effort to improve EAC risk stratification,
has been the lack of correlation between symptom severity and cancer risk22; patients are
more likely to seek medical care and ultimately be chosen for endoscopic screening if their
symptoms are severe and poorly controlled. However, many patients have abnormal
esophageal exposure to gastric juice in the face of mild or absent GERD symptoms. In the
present study, it is likely that heartburn was either entirely absent or controlled with medical
therapy, and the only manifestation of continued pathologic reflux was the LPR symptoms
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that ultimately triggered otolaryngology consultation.2,23 The results of the present study
support that no questionnaire or single symptom score, serving as an indicator of severity,
will aid in diagnosis of BE; we should instead focus our efforts on the identification of
symptom category (i.e., LPR and/or GERD) and duration. Given that BE was more
prevalent in those with LPR symptoms (with or without co-existing GERD) compared to
those with isolated GERD symptoms, otolaryngology patients with a long duration of
symptoms in the absence of an ear, nose or throat etiology could be a potential candidate for
screening endoscopy, particularly if these patients are taking proton pump inhibitors.
There is controversy as to whether biopsies should be obtained from an irregular Z-line
(ZAP classification I) as well as the oncologic significance of ultra short-segment BE.24 For
thoroughness, we biopsied all abnormal appearing squamocolumnar junctions based on
established criteria14; this action accounted for 14 of the 33 patients with BE and may have
resulted in over-diagnosis, which is a potential limitation of the present study. However, if
only patients with a ZAP classification greater than I were considered to be true BE, the
prevalence was 7% in this previously unscreened population; a prevalence that is
comparable to screening studies for BE in patients with chronic GERD.25,26
This study has characteristics that may limit generalizability of the findings. First, we
successfully enrolled only 56% of eligible subjects, and it is possible that patients who
agreed to participate were more likely to have long standing GERD symptoms that made
them more willing to be enrolled, although “duration” of symptoms was defined based on
information provided by subjects, potentially leading to recall bias. Despite this possibility
of selection and recall bias, these patients had never undergone a prior screening endoscopy
and the BE would have remained undetected. These findings likely recapitulate a “real
world” scenario where patients have medical control of heartburn but continue to have full-
column reflux events and present with predominate LPR symptoms. Long-segment
columnar-lined esophagus without goblet cells was identified in 9 patients. Several studies
have demonstrated that while the sample size is smaller with transnasal endoscope obtained
biopsies, there is an equivalent histologic yield compared to biopsies obtained with the
conventional sedated approach27,28; however it is possible that the needle forceps used in
the present study (1.9 mm in diameter) may result in the smaller biopsy specimens, and
additional biopsies would have revealed goblet cells in some of these patients, therefore
underestimating the prevalence of BE. Finally, the populations of patients approached for
enrollment were recruited from University and VA general otolaryngology clinics, and may
not reflect the ‘general population’ of patients with laryngeal symptoms.20 When analyzed
by institution and controlled for gender, no differences in either prevalence or associated
clinical risk factors were identified, suggesting that institutional differences between the
patient populations were minor with respect to our outcomes of interest.
In summary, we have found a high prevalence of BE in otolaryngology patients with
laryngeal symptoms. These patients may represent a significant subset of patient in whom
advanced EAC develops without a history of GERD or medically treated GERD.
Importantly, the patients recruited for this study represent a population for which endoscopic
screening would not have been recommended. Given that over 90% of subjects developing
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esophageal adenocarcinoma do not have a preceding diagnosis of BE,3 this subset of
patients represents a promising target for cancer prevention strategies.
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Reflux Symptom Index. Patients were asked to rate symptoms on a scale of zero (no
problem) to 5 (severe problem). All subjects who scored greater than 2 in at least two of
nine RSI symptom categories, or greater than 3 for any single RSI symptom category were
considered eligible in this study. A total RSI score >13 is defined as abnormal per
questionnaire scoring criteria.
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Flow chart of subject Screening, eligibility and study completion
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Table 1








Male sex 204 (73) 174 (71) 30 (91) 0.014*
Age [median (IQR)] 60 (51–68) 60 (50–67) 59 (52–72) 0.07
BMI [median (IQR)] 28.5 (25–32) 28.3 (25–32) 28.7 (25–31) 0.94
Caucasian Race 244 (96) 214 (96) 30 (97) 0.75
Typical GERD symptoms ever? 219 (79) 193 (79) 26 (79) 0.97
Cigarette Smoking
   Never 104 (37) 95 (39) 9 (27) 0.423
   Former 134 (48) 115 (47) 19 (58)
   Current 41 (15) 35 (15) 5 (15)
Current Alcohol Use 144 (52) 125 (51) 19 (59) 0.386
Co-morbidities
   Diabetes 36 (13) 33 (14) 3 (8) 0.482
   COPD 22 (8) 18 (7) 4 (12) 0.344
   Asthma 66 (24) 60 (25) 6 (19) 0.452
   Occupational lung injury 70 (26) 54 (23) 16 (50) 0.001*
   Seasonal allergy 93 (34) 83 (34) 10 (32) 0.822
Current Antisecretory medication use 156 (56) 138 (56) 18 (55) 0.266
Duration of medication use
    < 6 months 68 (35) 60 (35) 8 (40)
    6–12 months 18 (9) 15 (9) 3 (15)
    1–2 years 39 (20) 37 (22) 2 (10) 0.712
    3–5 years 35 (18) 31 (18) 4 (20)
    >5 years 32 (17) 29 (17) 3 (15)
    Never used 84 (30) 71 (29) 13 (39) 0.268
All values are reported as the number of patients (n) and percent (%) unless otherwise stated IQR: interquartile range, BMI: body mass index,
COPD: chronic obstructive pulmonary disease
*
p-value <0.05 was considered significant.
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Table 2
Endoscopic findings in otolaryngology patients with LPR symptoms undergoing primary screening




p-value Crude OR (95%
CI)
Zap Classification [n (%)]
   Grade 0 135 (100) 0 (0)
   Grade I 79 (85) 14 (15)
   Grade II 23 (74) 8 (26)
   Grade III 7 (39) 11 (61)
Length of CLE (cm) [median (IQR)] 0 (0–1) 1 (1–3) 0.026* 2.1 (1.5, 2.8)a
Hiatal hernia [n (%)] 129 (53) 25 (76) 0.015* 2.7 (1.2, 6.3)
Hiatal hernia size (cm) [median (IQR)] 1 (0–1) 2 (1–3) 0.027* 1.3 (1.0, 1.6)a
Abnormal RFS [median (IQR)] 10 (7–14) 10 (8–14) 0.341 1.0 (0.96, 1.1)b
Presence of esophagitis [n (%)] 65 (27) 12 (36) 0.300 1.6 (0.7, 3.4)
a
For each 1 cm increase in length of hiatal hernia or length of CLE
b
For each 1 point increase in the reflux findings score, GERD-HRQL, and reflux symptom index IQR=interquartile range; CLE=columnar lined
esophagus; RFS=reflux finding score
*
p-value `<0.05 was considered significant
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Table 3
Association between ZAP classification, duration of LPR symptoms and Barrett’s esophagus
LPR symptom duration by
ZAP classification
All Patients Negative BE Positive BE Odds Ratio
(95% CI)
Overall n=278 n=245 n=33†
   <5 years 189 (68) 176 (72) 13 (39)
   ≥5 years 89 (32) 69 (28) 20 (61) 3.9 (1.9, 8.3)
ZAP I or higher n=124 n=92 n=32
   <5 years 80 (65) 67 (73) 13 (41) .
   ≥5 years 44 (35) 25 (27) 19 (59) 4.5 (2.0, 10.1)
ZAP II or III n=42 n=24 n=18
   <5 years 24 (57) 19 (79) 5 (28) .
   ≥5 years 18 (43) 5 (21) 13 (72) 9.2 (2.4, 36.6)
†
Histologic intestinal metaplasia (n=31) or low-grade dysplasia (n=2). There were no patients with high-grade dysplasia or invasive cancer






















Nason et al. Page 15
Table 4





p-value Crude OR (95% CI)
Reflux Symptom Index (RSI) 19 (13–26) 22 (15–27) 0.515 1.0 (0.98, 1.1)††
  LPR symptoms
    Throat clearing 216 (88) 28 (85) 0.573 0.75 (0.27, 2.1)
    Post-nasal drip 199 (81) 79 (88) 0.471 1.7 (0.56, 5.0)
    Globus sensation 190 (78) 26 (79) 1.000 1.1 (0.44, 2.6)
    Hoarseness 183 (75) 29 (88) 0.126 2.5 (0.83, 7.3)
    Troublesome cough 168 (69) 28 (85) 0.067 2.6 (0.95, 6.9)
    Cough & hoarseness 135 (55) 24 (73) 0.062 2.2 (0.97, 4.9)
GERD-HRQL score 9 (3.5–16) 9 (4–12) 0.060 (0.92, 1.0)††
   Typical GERD symptoms 180 (74) 24 (73) 1.000 0.96 (0.43, 2.2)
††
For each 1 point increase in the reflux findings score, GERD-HRQL, and reflux symptom index RSI and GERD-HRQL scores are provided as
median (interquartile range)
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Table 5







Symptom Type Total BE Prevalence
[n (%)]
Distribution of Symptom type
[n (%)]
Abnormal questionnaire score 234 31 (13.2) 31 (94%) 203 (84%)
    Mixed GERD and LPR 147 19 (12.9) 19 (58%) 128 (53%)
    Isolated LPR 55 10 (18.2) 10 (30%) 45 (19%)
    Isolated GERD 32 2 (6.3) 2 (6%) 30 (12%)
Normal questionnaire score
    No pathological GERD or LPR 40 2 (5) 2 (6%) 38 (16%)
GERD: Gastroesophageal reflux disease, LPR: laryngopharyngeal reflux, BE: Barrett’s esophagus
Isolated GERD: Abnormal GERD-HRQL score with normal RSI score
Isolated LPR: Abnormal RSI score with normal GERD-HRQL score.
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